Announcement PDF ASX ANNOUNCEMENT Invion Limited ABN 76 094 730 417 Suite 2, Level 11, 385 Bourke Street Melbourne, VIC 3000 P: +61 3 9692 7222 W: www.inviongroup.com CREDENTIALED INTERNATIONAL BIOTECH LEADER JOINS INVION’S BOARD MELBOURNE (AUSTRALIA) 19 August 2026: Invion Limited (ASX: IVX) (“Invion” or the “Company”), a clinical-stage life sciences company developing its next-generation photodynamic therapy platform (NGPDT)called Photosoft™, is pleased to announce the appointment of Mr Paul Field as an Independent Non-Executive Director (INED), effective immediately. He joins the Board following the retirement of Mr Alistair Bennallack, who has served Invion since 2020 with dedication and professionalism during a period of significant operational and clinical progress. The Board thanks Mr Bennallack for his valuable contribution and wishes him well in his future endeavours. Strategic Relevance to Invion Mr Field brings more than 30 years of experience in the global biopharmaceutical industry, across commercialisation, investment and strategic partnering of new drug candidates and therapeutic programs. His appointment strengthens Invion’s Board at a pivotal time as the Company advances Photosoft™ through clinical development and expands its partnering footprint. His experience directly aligns with Invion’s priorities: • Global partnering expertise and deep relationships with biopharmaceutical companies in the USA, Europe and Asia. • Proven capability in negotiating licensing, co-development and commercial agreements. • Experience guiding clinical-stage companies through commercial and regulatory milestones. • Relationships with institutional investors in Australian life science companies. Mr Field is currently a NED at 60 Degrees Pharmaceuticals (NASDAQ: SXTP), the Executive Chair of Wintermute Biomedical Inc. and Head of Business Development at Alsonex Pty Ltd. He previously held senior positions at Neurizon Therapeutics Ltd., Horizon 3 Healthcare Fund and other biotech companies and organisations. Invion’s Executive Chair and CEO, Prof Thian Chew, said: “Paul is a strategically valuable addition to Invion’s Board. He brings a wealth of life sciences experience having successfully led and negotiated major deals across multiple therapeutic areas, and his insights and expertise will be invaluable as Invion moves toward broader clinical validation and commercial engagement. “On behalf of the Board, I also thank Alistair for his dedicated service and contributions to Invion’s progress from the early stages of Photosoft’s development within Invion.” This announcement was approved for release by Invion’s Board of Directors. ASX ANNOUNCEMENT Invion Limited ABN 76 094 730 417 Suite 2, Level 11, 385 Bourke Street Melbourne, VIC 3000 P: +61 3 9692 7222 W: www.inviongroup.com ____________________________________________ Sign up at Invion’s Investor Hub to receive regular updates, provide feedback and participate in discussions: https://investors.inviongroup.com/ Investor and Media enquiries: Thian Chew (Chairman & CEO) T: +61 3 9692 7222 E: investor@inviongroup.com Brendon Lau (Investor & Media Relations) M: +61 409 341 613 E: brendon.lau@inviongroup.com About Invion Invion is a life-science company leading global research and development of the Photosoft™ technology for the treatment of a range of cancers, atherosclerosis, and infectious diseases. Invion holds the global exclusive license to the Photosoft technology for multiple cancer and non-cancer disease indications. Invion is listed on the ASX (ASX: IVX). Find out more at www.Inviongroup.com. About Next Generation Photodynamic Therapy (NGPDT) Invion is developing its platform PhotosoftTM technology as a novel Next Generation Photodynamic Therapy (NGPDT). NGPDT uses non-toxic photosensitisers and light to selectively kill cancer cells and promote an anti-cancer immune response. Less invasive than surgery and with minimal side effects, NGPDT offers an alternative treatment option aimed at achieving complete tumour regression and long-lasting remission. NGPDT has also demonstrated potential in non-cancer disease areas including broad-spectrum activity across multiple infectious diseases, including bacteria, fungi and viruses. Photosoft has the potential to address the global challenge of antibiotic-resistant “superbugs”, in addition to other indications.